New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NDAQ;AAPL;BBRY;HD;GOOG;REGN;SNY;NVO;HEK;GMCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
November 19, 2014
09:38 EDTGOOGCCS Insight predicts Netflix to be acquired next year, FT reports
CCS Insight, a U.K.-based technology research firm, is predicting that a major internet player such as Yahoo (YHOO), Alibaba (BABA) or Google (GOOG) will buy Netflix (NFLX) next year, reported Financial Times. Reference Link
09:16 EDTBBRYOn The Fly: Pre-market Movers
Subscribe for More Information
08:17 EDTREGN, SNYRegeneron, Sanofi report new data from six alirocumab trials
Subscribe for More Information
08:02 EDTGOOG, AAPLApple's top competition is Google, says Jefferies
Jefferies calls Google (GOOG) Apple's (AAPL) top competition after its analysis indicated that the search engine giant provides the majority of most popular Consumer Cloud Services, which it believes are expanding penetration through Android, Chrome, iOS, Windows and other devices. By contrast, Apple's iCloud remains focused on iOS devices, Jefferies points out. It keeps a Hold rating on Apple shares, saying Google dominates as provider of the most popular services, including Search, Maps, Chrome, and YouTube. To reflect positive supply chain data points, Jefferies raised its FY15 earnings estimate for Apple to $8.52 to $8.01. It also upped its price target for Apple shares to $120 from $112. The stock closed yesterday up $1.48 to $115.47.
07:57 EDTBBRYBlackBerry downgraded at Morgan Stanley
Subscribe for More Information
07:52 EDTNVO, SNYInforma Business Information to hold a conference
Subscribe for More Information
07:47 EDTNDAQKeefe Bruyette to hold a conference
Securities Brokerage & Market Structure Conference is being held in New York on November 19 with webcasted company presentations to begin at 7:45 am. Webcast Link
07:39 EDTHDHome Depot weakness a buying opportunity, says UBS
UBS said it would use any weakness in Home Depot as a buying opportunity on the belief the company can continue to generate 15%-20% earnings growth. UBS reiterated its Buy rating and $108 price target on Home Depot shares.
07:11 EDTSNYSanofi drawing up list of CEO candidates to repalce Viehbacher, Reuters reports
Sanofi's (SNY) board is in the process of drawing up a short list of CEO candidates to replace Chris Viehbacher, sources tell Reuters. Jean-Rene Fourtou, a Sanofi director and the honorary chairman of media group Vivendi (VIVHY), has been selected to lead the appointments and governance committee that will select the next CEO. Smith & Nephew (SNN) CEO Olivier Bohuon, AstraZeneca (AZN) CEO Pascal Soriot and former Wyeth CEO Bernard Poussot have been rumored to be potential contenders for the CEO position. Reference Link
06:42 EDTAAPLiPhone 7 could include 'biggest camera jump ever,' TheTechBlock reports
Subscribe for More Information
06:40 EDTAAPLSome iPhone 6 Plus users say rear camera doesn't focus, Business Insider reports
Subscribe for More Information
06:13 EDTBBRYBlackBerry downgraded to Underweight from Equal Weight at Morgan Stanley
06:04 EDTAAPLApple to pay $23.6M to Mobile Telcommunictions in lawsuit, Re/code reports
Subscribe for More Information
November 18, 2014
17:22 EDTHDInvestors should think about buying Home Depot dip, Barron's says
Subscribe for More Information
16:26 EDTHDOn The Fly: Closing Wrap
Subscribe for More Information
16:00 EDTAAPLOptions Update; November 18, 2014
iPath S&P 500 VIX Short-Term Futures down 48c to 28.09. Option volume leaders: AAPL TSLA TWTR KO PBR GILD according to Track Data.
15:48 EDTSNYGenzyme, Isis present KYNAMRO data at AHA meeting
Genzyme, a Sanofi (SNY) company, and Isis Pharmaceuticals (ISIS) announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.
12:16 EDTSNYSanofi to host seminar on New Medicines
Subscribe for More Information
12:08 EDTHDOn The Fly: Midday Wrap
Subscribe for More Information
11:53 EDTAAPLSamsung to make foldable smartphone displays, ZDnet says
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use